Cancer Consultants Cancer News for Professionals

Denosumab More Effective than Zometa® in Patients with Bone Metastases

jmaxon@onco-ed.com (jenny maxon) — Fri, 10 Jul 2009 11:59:22 GMT

A press release from Amgen has reported that denosumab was more effective than Zometa® (zoledronic acid) for the prevention of bone complications in women with metastatic bone disease from breast cancer. These results were obtained in a large Phase III clinical trial comparing denosumab to Zometa for prevention of bone complications.

Meta-analysis Confirms that Diet and Lifestyle Choices Are Key to Preventing Colorectal Cancer

jmaxon@onco-ed.com (jenny maxon) — Fri, 10 Jul 2009 11:46:12 GMT

Researchers from Australia have reported that exercise, diet, and lifestyle choices are key factors in preventing colon cancer. The details of this study were published in the July 1, 2009 issue of the International Journal of Cancer.

Sutent® Not Effective for Patients with Unresectable Hepatocellular Carcinoma

jmaxon@onco-ed.com (jenny maxon) — Thu, 09 Jul 2009 15:35:21 GMT

Researchers from France have reported that treatment with Sutent® (sunitinib) of patients with advanced hepatocellular carcinoma was associated with a low response rate and significant toxicity. The details of this study appeared in an early online publication in Lancet Oncology on July 7, 2009.

Cervarix®, an HPV Vaccine, Prevents Precancerous Cervical Lesions

jmaxon@onco-ed.com (jenny maxon) — Thu, 09 Jul 2009 15:22:23 GMT

Researchers affiliated with the randomized PATRICIA trial have reported that Cervarix®, a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine made by GlaxoSmithKline has proven effective for preventing cervical intraepithelial neoplasia (CIN) 2+ in young women. The details of this study were published early online in the Lancet on July 7, 2009.

Single-dose Neulasta® Effective for Harvesting of Stem Cells in Children

jmaxon@onco-ed.com (jenny maxon) — Wed, 08 Jul 2009 09:07:58 GMT

Researchers from France have reported that a single dose of Neulasta® (pegfilgrastim) in the hematological steady state is “an efficient and well tolerated method of HPC (hematopoietic progenitor cell) mobilization in children with solid malignancies.” The details of this study appeared in the July 2009 issue of Bone Marrow Transplantation.

Nexavar® Confirmed Effective for FLT3-ITD-positive AML

jmaxon@onco-ed.com (jenny maxon) — Wed, 08 Jul 2009 08:57:43 GMT

Researchers from Germany have reported that Nexavar® (sorafenib) is an active agent for the treatment of acute myeloid leukemia (AML) in patients with internal tandem duplication (ITD) mutations in the Fms-like tyrosine-3 (FLT3) gene. The details of this study appeared in the June 25, 2009 issue of Blood.

Vegetarians May Have Lower Cancer Risk

jmaxon@onco-ed.com (jenny maxon) — Tue, 07 Jul 2009 11:03:03 GMT

Researchers from the United Kingdom have reported that vegetarians in that country and those who eat fish but not meat appear to have a lower risk of several types of cancer compared with meat eaters. The results of this study were published in the June 30, 2009 issue of the British Journal of Cancer.

Topical EGF May Decrease Severe Mucositis in Patients with Head and Neck Cancer Receiving Radiotherapy

jmaxon@onco-ed.com (jenny maxon) — Tue, 07 Jul 2009 10:55:21 GMT

Researchers from Korea have reported that recombinant epidermal growth factor (EGF) delivered as a spray twice daily may decrease the severity of severe mucositis in patients undergoing radiotherapy with or without chemotherapy for head and neck cancer. The details of this study appeared in an early online publication on June 9, 2009 in Cancer.

Alimta® and Platinol® Confirmed Less Toxic than Gemzar® and Platinol for Advanced NSCLC

jmaxon@onco-ed.com (jenny maxon) — Mon, 06 Jul 2009 13:41:00 GMT

Researchers from Norway have reported that the combination of Alimta® (pemetrexed) and Platinol® (carboplatin) is as effective as the combination of Gemzar® (gemcitabine) and Platinol but is associated with less hematopoetic toxicity and less need for supportive care. The details of this randomized trial were published in the July 1, 2009 issue of the Journal of Clinical Oncology.

Women Treated for Ductal Carcinoma In Situ (DCIS) Fail to Get Yearly Screening Mammography

jmaxon@onco-ed.com (jenny maxon) — Mon, 06 Jul 2009 13:32:15 GMT

Researchers from several U.S. medical centers have reported that women with DCIS treated with lumpectomy often fail to follow the guidelines for annual screening mammography. The details of this study appeared in the July 1, 2009 issue of the Journal of Clinical Oncology.